Matos Francisca Bartilotti, Mbanze Dara, Gomes Perpétua, Figueiredo Cristóvão, Coutinho Daniel, Nunes Sofia, Azevedo Carlos, Fragoso Joana, Teixeira Tiago, Malheiro Luís
Serviço de Doenças Infeciosas, Unidade Local de Saúde Gaia/Espinho, Vila Nova de Gaia, Portugal.
Laboratório de Biologia Molecular, Serviço de Patologia Clínica, Unidade Local de Saúde Lisboa Ocidental, Hospital Egas Moniz Lisbon, Portugal.
Int J STD AIDS. 2025 Feb;36(2):161-163. doi: 10.1177/09564624241296583. Epub 2024 Nov 1.
Resistance to antiretroviral therapy is an increasing challenge in the management of HIV. We present the case of a woman living with HIV, with a history of multiple treatment regimens and resistances to antiretrovirals, who has been successfully treated with a combination of lenacapavir and fostemsavir for the past year, obtaining an undetectable viral load within one month of starting therapy and reporting no serious side effects. This case is amongst the first to document the combined use of lenacapivir and fostemsavir in treating multidrug-resistant HIV. It supports the potential of these novel agents in managing complex cases of HIV resistance.
抗逆转录病毒治疗耐药性是艾滋病毒管理中日益严峻的挑战。我们报告了一名感染艾滋病毒的女性病例,她有多种治疗方案的病史且对抗逆转录病毒药物耐药,在过去一年中接受了来那卡韦和福斯特韦的联合治疗并取得成功,在开始治疗后的一个月内病毒载量降至无法检测水平,且未报告严重副作用。该病例是最早记录来那卡韦和福斯特韦联合用于治疗多重耐药艾滋病毒的病例之一。它支持了这些新型药物在处理复杂艾滋病毒耐药病例方面的潜力。